PerkinElmer has launched Signals Image Artist software, an image analysis and management platform for drug discovery research. The new offering is designed to help scientists accurately process and analyse their high-content screening (HCS) and cellular imaging data in a matter of hours, versus days or weeks, so they can make more informed decisions faster. The Signals Image Artist offering is part of the company’s Signals Informatics portfolio.
The Signals Image Artist software is designed for the big data demands drug discovery labs are working with today, including 3D cell, phenotypic and cell painting images. Its user interface requires minimal user training and the software supports multiple users processing, analysing, sharing, and storing information at the same time without compromised performance.
The Signals Image Artist software is also compatible with all major HCS and cell imaging systems on the market today, supporting users in multivendor lab environments.
“Today’s drug discovery labs are generating massive amounts of image data driven by a rise in the use of physiologically relevant models and the increasing adoption of cell painting and phenotypic screening approaches to try and reduce clinical trial failure rates,” said Alan Fletcher, Senior Vice President of Life Science, PerkinElmer. “Our new Signals Image Artist platform is designed to help drug discovery researchers drive more efficiently and effectively towards the next new novel therapeutic candidate by dramatically speeding up image processing, delivering quick and accurate data, and fostering easier collaboration.”
